PLRX (Pliant Therapeutics) GF Value Rank: 2 (As of Jul. 10, 2026) — 100% Above Median


PLRX Pliant Therapeutics Inc PLRX
31 GF Score
Price $1.12
! 2 Warning Signs
View Full Analysis

What is Pliant Therapeutics GF Value Rank?

Pliant Therapeutics PLRX 31 GF Value Rank is 2 as of Jul. 10, 2026, which is 100% above its 10-year median of 1.00. GuruFocus rates PLRX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Pliant Therapeutics has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Pliant Therapeutics GF Value Rank Related Terms


PLRX vs BYSI, MCRB, XBIT: GF Value Rank Comparison

For the Biotechnology subindustry, Pliant Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pliant Therapeutics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Pliant Therapeutics's GF Value Rank falls into.


PLRX
31GF Score
Pliant Therapeutics Inc PLRX
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Pliant Therapeutics (PLRX) has a GF Value Rank of 2 as of Jul. 10, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Pliant Therapeutics and its competitors. This is 100% above median its historical median of 1.00. Over the past decade, Pliant Therapeutics' GF Value Rank has ranged from 1.00 to 4.00.
Is Pliant Therapeutics' GF Value Rank too high?
Pliant Therapeutics' current GF Value Rank of 2 is 100% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. Overall, Pliant Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pliant Therapeutics' GF Value Rank compare to BYSI and MCRB?
Pliant Therapeutics' GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Pliant Therapeutics' own GF Value Rank has ranged from 1.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Pliant Therapeutics and its competitors. Pliant Therapeutics's current GF Value Rank is 2, which is 100% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pliant Therapeutics stock overvalued right now?
Pliant Therapeutics (PLRX) has a current GF Value Rank of 2. The current GF Value Rank is 2, which is 100% above median its 10-year median of 1.00. Pliant Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Pliant Therapeutics (PLRX), the current GF Value Rank is 2 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pliant Therapeutics Business Description

Other Exchanges 9PT:Germany
Address 331 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
31GF Score

Get the complete analysis for PLRX

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price